PTC Inc. stock is a Buy as Creo & Windchill drive R&D lock-in, 27% RPO growth, and 95% recurring revenue, plus $365M buybacks. Click here to read more on PTC.
By 2050, scientists estimate that antibiotic-resistant infections will be associated with more than 8 million deaths around the world every year.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results